Mavacamten reduces systolic contraction and might cause worsening heart failure or a complete block of ventricular function. A decrease of up to 10 % in LVEF has been reported. The most common side effects in the phase III EXPLORER trial were dizziness (27 %) and syncope (6 %).

- Acute stress cardiomyopathy

- Atrial fibrillation

- Ventricular tachycardia

- Angina pectoris

- Headache

- Dyspnea

- Chest pain

- Fatigue

- Palpitations

- Leg edema